May 2017 P&T Updates

Similar documents
November 2018 P & T Updates

January 2018 P & T Updates

July 2017 P&T Updates

ANTICONVULSANTS. Details

TEST ANTICONVULSANT THERAPY. Products Affected. Step 2: Network Health Insurance Corporation NetworkCares Step Therapy Criteria Last Updated 11/2018

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

ANTICONVULSANT STEP THERAPY

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 04/01/2019

FirstCarolinaCare Insurance Company. Step Therapy Requirements

Santa Clara Family Health Plan Cal MediConnect Formulary. List of Step Therapy Requirements Effective: 12/01/ E

See Important Reminder at the end of this policy for important regulatory and legal information.

ALLERGIC CONJUNCTIVITIS AGENTS

HEALTH SHARE/PROVIDENCE (OHP)

Generic Name (Brand Name) Available Strengths Formulary Limits. Primidone (Mysoline) 50mg, 250mg -- $

Self Report Seizure Survey Summary 2017

Step Therapy Requirements. Effective: 03/01/2015

Modified release drug delivery system for antiepileptic drug (Formulation development and evaluation).

ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY

March 2017 P&T Updates

Antiepileptics. Medications Comment Quantity Limit Carbamazepine. May be subject Preferred to quantity limit Epitol

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

ANTICONVULSANTS. Details

2017 Step Therapy Criteria

See Important Reminder at the end of this policy for important regulatory and legal information.

Integrating Sentinel into Routine Regulatory Drug Review: A Snapshot of the First Year. Risk of seizures associated with Ranolazine (Ranexa)

Prescribing Guide Standard Control Change Summary Report Effective (Standard Drug List Reflects Removals)

THERAPEUTIC AREA NAME STRENGTH DOSAGE FORM

ANTICONVULSANT THERAPY

Step Therapy Requirements

Therapeutic drug monitoring of Antiepileptic drugs in serum: a fully automated approach

See Important Reminder at the end of this policy for important regulatory and legal information.

New Patient Questionnaire - Epilepsy

STEP THERAPY CRITERIA

DPP4 INHIBITORS. Details. Step Therapy Criteria Health Alliance Plan 2019 Date Effective: 04/01/2019

Epilepsy 101. Overview of Treatment Kathryn A. O Hara RN. American Epilepsy Society

DPP4 INHIBITORS. Products Affected Step 2: Janumet 50 mg-1,000 mg tablet Janumet 50 mg-500 mg tablet Januvia 100 mg tablet Januvia 25 mg tablet

Disclosure. Learning Objectives

Appendix. TABLE E-1 Study Variables and Associated ICD-9-CM, HCPCS, and CPT Codes. Codes. (1) Fracture locations

Epilepsy: pharmacological treatment by seizure type. Clinical audit tool. Implementing NICE guidance

March 2018 P & T Updates

Alaska Medicaid 90 Day** Generic Prescription Medication List

Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18

HMO and PPO Formulary Updates November Commercial Results

Step Therapy Requirements. Effective: 12/01/2016

Clinical Policy: Clobazam (Onfi) Reference Number: CP.PMN.54 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Clobazam (Onfi) Reference Number: CP.PMN.54 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Epilepsy Society Therapeutic Drug Monitoring Unit (TDM Unit) Chalfont Centre for Epilepsy Chesham Lane Chalfont St Peter Buckinghamshire, SL9 ORJ

11/7/2018 EPILEPSY UPDATE. Dr.Ram Sankaraneni. Disclosures. Speaker bureau LivaNova

STEP THERAPY CRITERIA

Pharmacy Medical Necessity Guidelines: Anticonvulsants/Mood Stabilizers

2018 CareOregon Advantage Part D Formulary Changes

Monitoring of plasmatic concentrations of AEDs is important to improve patient s theraphy.

Neighborhood Medicaid Formulary Changes: June 2017

THERAPEUTIC AREA NAME STRENGTH DOSAGE FORM

Pharmacological Treatment of Non-Lesional Epilepsy December 8, 2013

2018 American Academy of Neurology

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

Medicare Part D Drugs that Require Step Therapy Effective 12/01/2017

The Epilepsy Prescriber s Guide to Antiepileptic Drugs

APPENDIX T - Unit costs of anti-epileptic drugs for 2012 guideline

Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

TOP APS DRUGS - DIVALPROEX SODIUM BRAND NAME: DEPAKOTE (ER)

2018 PDP Premier Step Therapy Document September 2018 Y0114_18_33144_I_009

ANTIDEPRESSANTS. Details. dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet. Criteria

EPILEPSY: SPECTRUM OF CHANGE WITH AGE. Gail D. Anderson, Ph.D.

Epilepsy. Seizures and Epilepsy. Buccal Midazolam vs. Rectal Diazepam for Serial Seizures. Epilepsy and Seizures 6/18/2008

TRANSPARENCY COMMITTEE OPINION. 19 July 2006

SEIZURES PHARMACOLOGY. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Ernie Somerville Prince of Wales Hospital EPILEPSY

Step Therapy Requirements. Effective: 1/1/2019

Step Therapy Requirements

May 2016 P & T Updates

Updated advice for nurses who care for patients with epilepsy

Management of Epilepsy in Primary Care and the Community. Carrie Burke, Epilepsy Specialist Nurse

Anticonvulsants Antiseizure

Epilepsy 101. Russell P. Saneto, DO, PhD. Seattle Children s Hospital/University of Washington November 2011

Valproate Case 3: Formulations Jose de Leon, MD

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

Clinical Policy: Pregabalin (Lyrica) Reference Number: LA.PMN.33 Effective Date: Last Review Date: 07.18

Step Therapy Requirements. Effective: 05/01/2018

The importance of pharmacogenetics in the treatment of epilepsy

HMO and PPO Updates September Commercial Results

Antiepileptic Drugs (Anticonvulsants )

Step Therapy Requirements. Effective: 11/01/2018

Transcription:

May 2017 P&T Updates Commercial Triple Tier 4th Tier Applicable Traditional Prior Auth Alternatives 6 ml per AMPYRA 3 2 2 tablets per day, 30 day BYDUREON 3 2 4 vials per 28 days 5 mcg pen: 1.2 ml per 10 mcg pen: 2.4 ml per 30 mg: 2 tablets per day ISENTRESS 25 MG 2 2 6 tablets per day - JADENU 3 2 - Exjade*, Ferriprox* KISQALI 3 2 Based on daily dose Ibrance* PATADAY *EFFECTIVE - olopatadine (generic Patanol) Renvela, calcium acetate, - Fosrenol RENVELA 3 2 - - REVLIMID 3 2 1 capsule per day, 28 day Xultophy*, Victoza*, 18 ml per Tanzeum*, Lantus*, Toujeo*, * TANZEUM 2 2 4 pens per 28 days metformin 1 1 - Seizures: carbamazepine, divalproex, felbamate, valproic acid, topiramate IR, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, zonisamide, gabapentin, tiagabine, phenobarbital Migraine: topiramate IR, propranolol, timolol, divalproex topiramate extended - release* TRULICITY 3 2 2 ml per 28 days VICTOZA 2 2 9 ml per metformin XULTOPHY 2 2 15 ml per Victoza*, Tanzeum*, Lantus, Toujeo,

CHIP Tier Prior Auth Alternatives - 6 ml per AMPYRA 2 2 tablets per day, 30 day BYDUREON 2 4 vials per 28 days - 5 mcg pen: 1.2 ml per 10 mcg pen: 2.4 ml per - 30 mg: 2 tablets per day ISENTRESS 25 MG 2 6 tablets per day - JADENU 2 - Exjade*, Ferriprox* KISQALI 2 Based on daily dose Ibrance* PATADAY *EFFECTIVE - - olopatadine (generic Patanol) - - Renvela, calcium acetate, Fosrenol RENVELA 2 - - REVLIMID 2 1 capsule per day, 28 day Xultophy*, Victoza*, Tanzeum*, Lantus*, - 18 ml per Toujeo*, * TANZEUM 2 4 pens per 28 days metformin 2 - Seizures: carbamazepine, divalproex, felbamate, valproic acid, topiramate IR, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, zonisamide, gabapentin, tiagabine, phenobarbital Migraine: topiramate IR, propranolol, timolol, divalproex - - topiramate extended release* TRULICITY 2 2 ml per 28 days VICTOZA 2 9 ml per metformin XULTOPHY 2 15 ml per Victoza*, Tanzeum*, Lantus, Toujeo,

GHP Family JADENU GHP Family Tier Prior Auth Alternative(s) 6 ml per 6 mg, 30 mg - 2 tablets daily, 18 mg - 1 tablet daily - KISQALI Brand 600 mg daily dose: 63 tablets, 400 mg daily dose: 42 tablets, 200 mg daily dose: 21 tablets. Maximum of 28 day. Ibrance* (EFFECTIVE Renvela, calcium acetate, - 9/1/17) Fosrenol RENVELA Brand - calcium acetate, Fosrenol Victoza*, Tanzeum*, 18 ml per Xultopy*, Lantus, Toujeo, TANZEUM Brand 4 pens per 28 days metformin ER Generic - Topiramate IR TRULICITY 2 ml per 28 days VICTOZA Brand 9 ml per metformin XULTOPHY Brand 15 ml per Victoza*, Tanzeum*, Lantus, Toujeo,

Geisinger Gold $0 Deductible BAVENCIO Specialty Standard Prior Auth Alternative(s) - - - - - - - - Specialty 6mg and 30 mg tablets: 2 per day; 18 mg tablets: 1 per day JADENU Specialty KISQALI Specialty (EFFECTIVE 1/1/18) XULTOPHY - - - - - 63 tablets/28 days - - - - - - - Brand Preferred ZINPLAVA Specialty - 15 ml every 30 days Deferoxamine*, Exjade*, Ferriprox* Ibrance* calcium acetate, Fosrenol, Renvela Lantus,, Toujeo, - - - -

Marketplace Tier Prior Auth Alternatives 6 ml per AMPYRA 3 2 tablets per day, 30 day BYDUREON 3 4 vials per 28 days Victoza*, Tanzeum* 5 mcg pen: 1.2 ml per 10 mcg pen: 2.4 ml per 30 mg: 2 tablets per day ISENTRESS 25 MG 3 6 tablets per day not applicable JADENU 5 - Exjade*, Ferriprox* KISQALI 5 Based on daily dose. Ibrance* PATADAY *EFFECTIVE - olopatadine (generic Patanol) - Renvela, calcium acetate, Fosrenol RENVELA 3 - - REVLIMID 5 1 capsule per day, 28 day Xultophy*, Victoza*, Tanzeum*, 18 ml per Lantus*, Toujeo*, * TANZEUM 3 4 pens per 28 days metformin 2 - Seizures: carbamazepine, divalproex, felbamate, valproic acid, topiramate IR, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, zonisamide, gabapentin, tiagabine, phenobarbital Migraine: topiramate IR, propranolol, timolol, divalproex - topiramare extended release* TRULICITY 3 2 ml per 28 days VICTOZA 3 9 ml per metformin XULTOPHY 3 15 ml per Victoza*, Tanzeum*, Lantus, Toujeo,